Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, First in Human (FIH), Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Preliminary Efficacy and Immunogenicity of TJ101 for Injection in Patients With Advanced/Metastatic Solid Tumors

NCT07181473 is registered in ClinicalTrials.gov with Phrontline Biopharma as lead sponsor.

NCT NCT07181473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07181473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, First in Human (FIH), Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Preliminary Efficacy and Immunogenicity of TJ101 for Injection in Patients With Advanced/Metastatic Solid Tumors
Lead sponsor
Phrontline Biopharma
Phase
Phase 1
Overall status
Recruiting
Start date
August 25, 2025
Completion date
September 15, 2027
Enrollment
200 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, lung cancer (nsclc), prostate cancer, solid tumor malignancies